SI2076271T1 - Inhibicija toksinov kolere z galatooligosaharidi (GOS) - Google Patents
Inhibicija toksinov kolere z galatooligosaharidi (GOS)Info
- Publication number
- SI2076271T1 SI2076271T1 SI200730768T SI200730768T SI2076271T1 SI 2076271 T1 SI2076271 T1 SI 2076271T1 SI 200730768 T SI200730768 T SI 200730768T SI 200730768 T SI200730768 T SI 200730768T SI 2076271 T1 SI2076271 T1 SI 2076271T1
- Authority
- SI
- Slovenia
- Prior art keywords
- gos
- galatooligosaccharides
- inhibition
- nutritional
- cholera toxin
- Prior art date
Links
- 206010008631 Cholera Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 239000003053 toxin Substances 0.000 title 1
- 231100000765 toxin Toxicity 0.000 title 1
- 108700012359 toxins Proteins 0.000 title 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 abstract 5
- 150000003271 galactooligosaccharides Chemical class 0.000 abstract 5
- 102000009016 Cholera Toxin Human genes 0.000 abstract 2
- 108010049048 Cholera Toxin Proteins 0.000 abstract 2
- 235000016709 nutrition Nutrition 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000030090 Acute Disease Diseases 0.000 abstract 1
- 231100000699 Bacterial toxin Toxicity 0.000 abstract 1
- 208000017667 Chronic Disease Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000000688 bacterial toxin Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000006116 polymerization reaction Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06076810 | 2006-10-02 | ||
| PCT/NL2007/050475 WO2008041843A1 (en) | 2006-10-02 | 2007-10-01 | Inhibition of cholera toxins by galatooligosaccharides (gos) |
| EP07834613A EP2076271B1 (en) | 2006-10-02 | 2007-10-01 | Inhibition of cholera toxins by galatooligosaccharides (gos) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2076271T1 true SI2076271T1 (sl) | 2011-12-30 |
Family
ID=37533486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200730768T SI2076271T1 (sl) | 2006-10-02 | 2007-10-01 | Inhibicija toksinov kolere z galatooligosaharidi (GOS) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8202842B2 (enExample) |
| EP (1) | EP2076271B1 (enExample) |
| JP (1) | JP2010505822A (enExample) |
| AT (1) | ATE524190T1 (enExample) |
| DK (1) | DK2076271T3 (enExample) |
| ES (1) | ES2373592T3 (enExample) |
| PL (1) | PL2076271T3 (enExample) |
| PT (1) | PT2076271E (enExample) |
| SI (1) | SI2076271T1 (enExample) |
| WO (1) | WO2008041843A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006012536A2 (en) | 2004-07-22 | 2006-02-02 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
| FR2907687B1 (fr) * | 2006-10-30 | 2008-12-26 | Applexion | Procede de purification de sialyllactose par chromatographie |
| US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
| KR20170053733A (ko) | 2009-02-24 | 2017-05-16 | 리터 파마슈티컬즈 인코오포레이티드 | 프리바이오틱 제제 및 사용 방법 |
| US8785160B2 (en) | 2009-02-24 | 2014-07-22 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| JP2012520325A (ja) † | 2009-03-13 | 2012-09-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | プレバイオティックオリゴ糖 |
| US20110189342A1 (en) * | 2010-02-01 | 2011-08-04 | Jeong Hea-Seok | High-purity galactooligosaccharides and uses thereof |
| NL2007931C2 (en) | 2011-12-07 | 2013-06-10 | Friesland Brands Bv | Methods for providing sialylated oligosaccharides and products obtainable thereby. |
| WO2015095747A1 (en) | 2013-12-20 | 2015-06-25 | Abbott Laboratories | Oral rehydration composition with oligosaccharides |
| EP3530743A1 (en) | 2018-02-21 | 2019-08-28 | Cambridge Glycoscience Ltd | Method of production |
| AU2019321182B2 (en) | 2018-08-15 | 2025-01-09 | Cambridge Glycoscience Ltd. | Novel compositions, their use, and methods for their formation |
| CA3108735A1 (en) | 2018-09-06 | 2020-03-12 | Frieslandcampina Nederland B.V. | Bifidogenic hypoallergenic gos compositions and methods for providing the same involving beta-galactosidase from a strain of lactobacillus delbrueckii ssp bulgaricus |
| KR102874614B1 (ko) * | 2018-11-08 | 2025-10-22 | 디에스엠 아이피 어셋츠 비.브이. | 위장 대사물질을 조절하는 방법 |
| US11911405B2 (en) * | 2018-11-08 | 2024-02-27 | Dsm Ip Assets B.V. | Methods of selectively modulating gastrointestinal microbial growth |
| EP4013240A1 (en) | 2019-08-16 | 2022-06-22 | Cambridge Glycoscience Ltd | Methods of treating biomass to produce oligosaccharides and related compositions |
| CN115279208B (zh) | 2019-12-12 | 2024-12-17 | 剑桥糖质科学有限公司 | 低糖多相食品 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0614870B2 (ja) * | 1986-12-15 | 1994-03-02 | 株式会社ヤクルト本社 | ガラクトオリゴ糖の製造法 |
| NZ222902A (en) | 1986-12-15 | 1990-08-28 | Yakult Honsha Kk | Method for producing galactooligosaccharide |
| ZA991410B (en) | 1998-02-23 | 1999-10-06 | Synsorb Biotech Inc | Compounds and methods for the treatment of bacterial dysentry using antibiotics and toxin binding oligosaccharide compositions. |
| US6630452B2 (en) * | 2000-02-17 | 2003-10-07 | Wyeth | Nutritional formulation containing prebiotic substances |
| FR2838452B1 (fr) | 2002-04-10 | 2004-07-09 | Eurodia Ind | Procede de production en continu de galacto oligosaccharides |
| GB0229015D0 (en) | 2002-12-12 | 2003-01-15 | Novartis Nutrition Ag | New Compound |
| GB0308104D0 (en) * | 2003-04-08 | 2003-05-14 | Novartis Nutrition Ag | Organic compounds |
| MXPA05010349A (es) | 2003-06-30 | 2006-03-08 | Clasado Inc | Composicion novedosa de galactooligosacaridos y preparacion de la misma. |
| JP4847321B2 (ja) | 2003-07-04 | 2011-12-28 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼーション | 金属化合物を製造するための方法および装置 |
| US20070196890A1 (en) | 2003-10-02 | 2007-08-23 | Jelena Vulevic | Prebiotic effect analysis |
-
2007
- 2007-10-01 SI SI200730768T patent/SI2076271T1/sl unknown
- 2007-10-01 JP JP2009531332A patent/JP2010505822A/ja active Pending
- 2007-10-01 US US12/443,565 patent/US8202842B2/en not_active Expired - Fee Related
- 2007-10-01 EP EP07834613A patent/EP2076271B1/en not_active Not-in-force
- 2007-10-01 ES ES07834613T patent/ES2373592T3/es active Active
- 2007-10-01 PT PT07834613T patent/PT2076271E/pt unknown
- 2007-10-01 WO PCT/NL2007/050475 patent/WO2008041843A1/en not_active Ceased
- 2007-10-01 PL PL07834613T patent/PL2076271T3/pl unknown
- 2007-10-01 DK DK07834613.7T patent/DK2076271T3/da active
- 2007-10-01 AT AT07834613T patent/ATE524190T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PL2076271T3 (pl) | 2012-02-29 |
| US8202842B2 (en) | 2012-06-19 |
| JP2010505822A (ja) | 2010-02-25 |
| ATE524190T1 (de) | 2011-09-15 |
| ES2373592T3 (es) | 2012-02-06 |
| EP2076271A1 (en) | 2009-07-08 |
| PT2076271E (pt) | 2011-12-02 |
| WO2008041843A1 (en) | 2008-04-10 |
| EP2076271B1 (en) | 2011-09-14 |
| US20100069322A1 (en) | 2010-03-18 |
| DK2076271T3 (da) | 2012-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2076271T3 (pl) | Hamowanie toksyn cholery przez galaktooligosacharydy (GOS) | |
| WO2004103294A3 (en) | Methods and compositions for the prevention and treatment of sepsis | |
| ATE375164T1 (de) | Endotoxin-bindung durch milchsäurebakterien und bifidobacteria | |
| WO2006128032A3 (en) | Compositions and methods for the prevention and treatment of conditions associated with inflammation | |
| WO2008089310A3 (en) | Delta 5 desaturase inhibitors for the treatment of obesity | |
| MY147489A (en) | Methods for the treatment of muscle loss | |
| MY148872A (en) | Use of bifidobacterium longum for the prevention and treatment of inflammation | |
| WO2008054208A3 (en) | Use of nutritional compositions for preventing disorders | |
| MY169746A (en) | Dual variable domain immunoglobulin and uses thereof | |
| EP2982696A3 (en) | Treatment of acute lymphoblastic leukemia | |
| BR0304648A (pt) | Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia | |
| WO2010023422A8 (en) | Use of prebiotic galacto-oligosaccharides in the treatment of intestinal inflammation | |
| WO2009080800A3 (en) | Method for decreasing abdominal girth by administering a bifidobacterium bacteria | |
| WO2008079270A3 (en) | Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis | |
| WO2008008772A3 (en) | Methods for treating and limiting fibrotic disorders and keloids | |
| WO2007100765A3 (en) | Lysozyme-modified probiotic components and uses thereof | |
| WO2007059154A3 (en) | Treatment of cancers with acquired resistance to kit inhibitors | |
| ATE542832T1 (de) | Nahrungsmittel zur inhibierung der osteoclastbildung | |
| WO2008018111A3 (en) | Composition containing cranberry (vaccinium macrocarpon) and lactoferrin for the prevention and treatment of urinary tract infections | |
| WO2006071456A3 (en) | Inhibition of hsp27 phosphorylation for treatment of blistering disorders | |
| WO2008063853A3 (en) | Cancer treatment method | |
| WO2006124375A3 (en) | Substances, compositions and methods for preventing and treating immune-mediated inflammatory disorders | |
| WO2009076243A3 (en) | Novel uses of chloramphenicol and analogues thereof | |
| WO2009033047A3 (en) | Methods and compositions for treating diseases and conditions involving higher molecular weight hyaluronan | |
| EP2500354A3 (en) | Dual variable domain immunoglobulin and uses thereof |